Raymond Chee Seong Seet

Raymond Chee Seong Seet

Auto-generated profile, based on publicly available information

Raymond Chee Seong Seet

Division of Neurology, Department of Medicine, National University Hospital, Singapore

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RSRaymond C.S. Seet
Raymond C.S. Seet
Jetty Chung-Yung LeeJetty Chung-Yung Lee
Jetty Chung-Yung Lee
ELErle C.H. Lim
Erle C.H. Lim
JTJune J.H. Tan
June J.H. Tan
AQAmy M.L. Quek
Amy M.L. Quek
BHBarry Halliwell
Barry Halliwell

1 August 2012 in Cerebrovascular Diseases
Verified
Journal Article
Open access
PDF file
RSRaymond C.S. Seet
Raymond C.S. Seet
ARAlejandro A. Rabinstein
Alejandro A. Rabinstein
Background: Symptomatic intracranial hemorrhage (SICH) is a devastating complication of intravenous thrombolysis treatment that is associated with high mortality. Clinical trials, stroke registries and cohort studies employ different case definitions to identify stroke patients with SICH following intravenous thrombolysis. We systematically reviewed the reported rates of SICH following intravenous thrombolysis and compared their consistency with mortality outcomes. Methods: Studies were identified from the PubMed and Embase databases from January 1994 to July 2011 by cross-referencing the following MeSH terms: ‘thrombolysis’, ‘recombinant tissue plasminogen activator’, ‘rtPA’, ‘hemorrhagic stroke’, ‘cerebral hemorrhage’, ‘hematoma’ and ‘ischemic stroke’. Demographic information, baseline National Institute of Health Stroke Scale (NIHSS) scores, time from stroke onset to intravenous thrombolysis, SICH and mortality rates were derived from published data in 7 randomized controlled trials, 7 stroke registries and 10 cohort studies (4 multicenter and 6 single center) with more than 200 consecutively recruited patients. Mortality rates were considered as the percentage of patients treated with intravenous thrombolysis who died within 90 days after stroke. Results: The mean age of patients included in this analysis was 68.8 years (standard deviation, SD 2.9, range 63–75), of whom 56.3% (SD 4.5, range 45–63) were men. They presented with a mean baseline NIHSS of 12.5 (SD 1.4, range 9–15) and received intravenous thrombolysis 175 min (SD 62, range 120–328) from stroke onset. The overall mean SICH and mortality rates of patients treated with intravenous thrombolysis were 5.6% (SD 2.3) and 14.7% (SD 4.8), respectively. A moderate correlation was observed between the incidence of SICH and mortality in patients treated with intravenous thrombolysis (r = 0.401, p = 0.050). The variation in SICH rates was highest across studies that reported SICH rates using the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria compared with the European Cooperative Acute Stroke Study and National Institute of Neurological Disorders and Stroke (NINDS) criteria. Studies that defined SICH as parenchymal hemorrhage with a neurological decline NIHSS ≥4 occurring within 36 h of intravenous thrombolysis reported a higher consistency between SICH and mortality rates (correlation coefficient 0.631). Conclusions: SICH rates vary considerably between studies and these differences may relate to the differences in the criteria used to define SICH. Until a case definition with high interrater agreement and good correlation with stroke outcomes becomes available, detailed information on the type of bleeding, the extent of NIHSS deterioration, neuroimaging features and the time from thrombolysis to diagnosis of hemorrhage should be reported to permit a correct interpretation of SICH rates.

1 January 2007 in Journal of Clinical Virology
Verified
Journal Article
Closed access
RSRaymond C.S. Seet
Raymond C.S. Seet
AQAmy M.L. Quek
Amy M.L. Quek
ELErle C.H. Lim
Erle C.H. Lim

1 May 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
RSRaymond Chee Seong Seet
Raymond Chee Seong Seet
AQAmy May Lin Quek
Amy May Lin Quek
DODelicia Shu Qin Ooi
Delicia Shu Qin Ooi
SSSharmila Sengupta
Sharmila Sengupta
SLSatish Ramapatna Lakshminarasappa
Satish Ramapatna Lakshminarasappa
MHMikael Hartman
Mikael Hartman
We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19). An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined as individual floors of the dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 μg/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day. The primary outcome was laboratory evidence of SARS-CoV-2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42. A total of 3037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis. Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2-42%) and povidone-iodine throat spray (24%, 7-39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, -5 to +41%) and ivermectin (5%, -10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%), and hydroxychloroquine (0.7%). Chemoprophylaxis with either oral hydroxychloroquine or povidone-iodine throat spray was superior to oral vitamin C in reducing SARS-CoV-2 infection in young and healthy men.

1 November 2011 in Atherosclerosis
Verified
Journal Article
Closed access
RSRaymond C.S. Seet
Raymond C.S. Seet
Jetty Chung-Yung LeeJetty Chung-Yung Lee
Jetty Chung-Yung Lee
ELErle C.H. Lim
Erle C.H. Lim
AQAmy M.L. Quek
Amy M.L. Quek
HHHuiwen Huang
Huiwen Huang
BHBarry Halliwell
Barry Halliwell

24 August 2011 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
RSR. C. S. Seet
R. C. S. Seet
ARA. A. Rabinstein
A. A. Rabinstein
Background: Posterior reversible encephalopathy syndrome (PRES) is a potentially devastating complication of bevacizumab treatment. Aim: We examined the clinical features, treatment and outcomes of patients who developed PRES following bevacizumab treatment at our institution and those reported in the literature. Design: Retrospective audit and systematic review. Methods: Patients were identified from the Mayo Clinic database and the published literature using ‘PubMed’ and ‘OVID’ databases, from January 2006 to June 2010, who developed PRES features within 3 weeks of bevacizumab treatment, who had brain imaging findings of focal vasogenic edema and radiologic proof of reversibility. Results: Two patients with definite PRES were identified from our institution and a further 10 cases were identified from the published literature (total, n = 12). The mean age of these patients was 52 years (range 4–68 years), four of whom were men and eight women. Headaches (n = 7), seizures (n = 6), visual disturbances (n = 5) and nausea and vomiting (n = 3) were the common presenting symptoms. In a majority of patients (n = 10), an increase in blood pressure from their baseline values was observed during their acute presentation. PRES resolved following withdrawal of bevacizumab and blood pressure control in all patients. Conclusions: PRES is a catastrophic neurological complication of bevacizumab treatment, which responds favorably to prompt bevacizumab withdrawal and blood pressure control.